- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A New Decision Support Tool for Surgical Oncology Launched
A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.
Clinical pathways are rapidly being adopted by providers and payers alike, to guide treatment decisions and also manage care costs. Via Oncology, a company that develops these clinical pathways using its in-house expertise of physicians, has announced the launch of a Surgical Oncology Pathways platform, which follows similar platforms for medical and radiation oncology.
In an associated press release the company said that the new platform is initially being rolled out at UPMC and Indiana University Health, for 6 diseases, incorporating key decision points for patient work-up and assessment along with surgical interventions and follow up surveillance plans.
According to Kathy Lokay, CEO and President of Via Oncology, “The Via Pathways program has been central to the quality of care in medical and radiation oncology and we are excited to expand it for use by surgical oncologists as well.”
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
